Citations

Clear

334 citation(s) found for "Jacobs, C".

The Congenital Heart Surgeons’ Society Center for Research and Quality 2025 Annual Report
Jacobs, Jeffery P , DeCampli, William M , Honjo, Osami , Alsoufi, Bahaaldin , Jegatheeswaran, Anusha , Louis, James D. St. , Lambert, Linda M , Manlhiot, Cedric , Kumar, S Ram , Kirklin, James K. , Austin, Erle H , Overman, David M , Dearani, Joseph A. , Romano, Jennifer C , Blackstone, Eugene H.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | October 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/21501351261477040 | PMID 42876309 Get It

The Congenital Heart Surgeons’ Society (CHSS) is viewed by many as one of the most prestigious professional societies dedicated to pediatric and congenital cardiac surgery. The CHSS Center for Research and Quality (CRQ) Fall 2025 Work Weekend was held in Chicago on Saturday, October 25, 2025. The purpose of this article is to summarize the proceedings of the CHSS CRQ Fall 2025 Work Weekend and to provide a 2025 Annual Report of the CHSS CRQ. At the CHSS CRQ Fall 2025 Work Weekend, multiple topics were discussed related to ongoing CHSS research and quality initiatives. The CHSS CRQ is evolving to keep pace with the rapid evolution of medical informatics and the ever-evolving regulatory issues of clinical research. This 2025 Annual Report of the CHSS CRQ summarizes some of the ongoing initiatives at CHSS CRQ designed to assure that the CHSS CRQ continues to lead innovative and collaborative clinical research to improve pediatric and congenital cardiac care.
Maladaptive Piezo1 Mechanotransduction Drives Smooth Muscle Aging in the Gut
Joshi, Vikram , Seavey, Corey, Knutson, Kaitlyn, Sawant, Abhilash, Hamed, Yasmeen M F , D'Ambrosio, Mario, Laible, Emma, Sinnwell, Jason Paul, Liu, Yuanhang , Jin, Franco F, Thomas, C. T., Garramone, Gwyneth, Mazzone, Amelia Paul, Du, Peng , Grover, Madhusudan , Kashyap, Purna , Druliner, Brooke R. , Cipriani, Gianluca , Marshall, Kara L. , Farrugia, Gianrico, Joshi, Vikram , Seavey, Corey , Knutson, Kaitlyn R. , D’Ambrosio, Mario , Sinnwell, Jason P. , Garramone, Gwyneth K., Mazzone, Amelia , Bonfiglio, Ferdinando , D’Amato, Mauro , Avci, Recep , Linden, David R. , Bae, Yongho , Farrugia, Gianrico , Beyder, Arthur , Dokic, Vladimir, Druliner, Brooke , Beyder, Arthur

Mayo Clinic

No container title available | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.02.748183 | PMID 42818261 Get It

Age-related gastrointestinal dysfunction is common, but the mechanisms of aging-associated smooth muscle failure remain unclear. We show that aging in mice slows whole gut and colonic transit, increases regional stiffness, and reduces smooth muscle contractility. Inducible smooth muscle cell (SMC)– specific deletion of Piezo1 preserved youthful transit and force generation, whereas Piezo1 activation in young mice phenocopied aging-associated transit delay. Single-cell transcriptomics, RNA velocity, stiffness-controlled cell and tissue cultures, and pharmacologic studies revealed that Piezo1 couples increased stiffness to Ca 2+ –calcineurin–NFAT signaling, loss of contractile gene programs, leading to age- related contractile loss and contractile-to-synthetic SMC remodeling and gut wall stiffening. Human intestinal SMCs supported conservation of this pathway, and PIEZO1 gain-of-function carriers showed a trend toward delayed colonic transit. Thus, maladaptive SMC Piezo1 mechanotransduction is a targetable mechanism of aging-associated gut dysmotility. Aging alters organ structure, yet how these changes drive functional decline remains poorly defined. We show that progressive stiffening of the gut with age activates the mechanosensitive ion channel Piezo1 in smooth muscle cells, initiating a maladaptive response that impairs contractility and slows intestinal transit. On the other hand, deletion of smooth muscle Piezo1 prevents age-related gut dysmotility. These findings reveal that age-related physical shifts actively drive functional decline through mechanotransduction pathways. By identifying Piezo1 as a critical link between tissue mechanics and organ aging, this work provides a framework for understanding how mechanical cues contribute to age-related dysfunction in the gut and possibly other smooth muscle organs.
Neuromodulatory subcortical systems in Alzheimer's disease
Ehrenberg, Alexander J. , Jacobs, Heidi I. L., Grinberg, Lea T., Falgàs, Neus , Jacobs, Heidi I.L. , Grinberg, Lea T.

Mayo Clinic

Alzheimer's & Dementia | August 8, 2026 | Volume: 22 | Issue: 8 | Pages: No page available

10.1002/alz.71747 | PMID 42569829 Get It

Long‐Term Cancer and Mortality After Thymectomy
Shelly, Shahar , Ani, Mor, Li, Yuebing , Kaminski, Henry J. , Wolfe, Gil I. , Miron, Keren, Ramon‐Gonen, Roni , Klein, Christopher J , Li, Yuebing , Kaminski, Henry , Wolfe, Gil I , Ramon-Gonen, Roni , Shahar, Shelly , Klein, Christopher J.

Mayo Clinic

European Journal of Neurology | August 1, 2026 | Volume: 33 | Issue: 8 | Pages: No page available

10.1111/ene.70721 | PMID 42538851 Get It

ABSTRACT Background Long‐term health effects of thymectomy in adults remain uncertain. Previous reports suggested associations with increased mortality, cancer incidence, and autoimmune disease, although these findings may reflect differences in patient selection, surgical indication, or follow‐up duration. We aimed to examine long‐term outcomes following adult thymectomy. Methods We performed a propensity score‐matched retrospective study of patients who underwent thymectomy or comparator cardiothoracic procedures, with follow‐up extending to 10 years. Primary outcomes were all‐cause mortality, new‐onset malignancy, and autoimmune disease. Findings were compared with those reported in a recent study that has raised caution regarding thymic excision. Results We identified 425 patients who underwent thymectomy and 5401 controls who underwent coronary artery bypass or valve surgery. After matching, 398 patients remained in each group. Thymectomy was not associated with increased mortality at 5 years ( HR = 0.63; 95% CI , 0.38–1.04) or 10 years ( HR = 0.78; 95% CI , 0.54–1.13). Excluding reclassified thymic cancers, 5‐year extrathymic malignancy incidence was 2.3% versus 1.8% ( p = 0.54); no significant differences were observed in immune‐related disease. Mortality was higher among patients with thymic malignancy. Among MG patients, only one event occurred, precluding reliable estimation. Conclusions Thymectomy was not associated with excess mortality or malignancy at 10 years compared with matched cardiothoracic controls. Indication‐stratified analyses within the thymectomy cohort showed higher mortality for thymic malignancy, with insufficient events to assess outcomes in MG patients. These findings do not support a generalized survival penalty from thymectomy, though caution is warranted for incidental thymic removal.
“It’s Scary, but I Handle It”: A Qualitative Study on Severe Hypoglycemia Experiences and Reasons for Declining to Participate in a Community Paramedicine Trial to Prevent Hypoglycemia Among People With Diabetes
Huang, Grace L., Tokar, Kathleen, Jacobs, Davi, Krpata, Tami, Sundt, Wendy J., McCoy, Rozalina G. , McCoy, Rozalina Grubina , Golembiewski, Elizabeth H. , Golembiewski, Elizabeth H , Krpata, Tami S, Sundt, Wendy J S

Mayo Clinic

Diabetes Obesity and Cardiometabolic CARE | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/doc26-0061 | PMID 42892872 Get It

OBJECTIVE Severe (level 3) hypoglycemia is a life-threatening complication of diabetes associated with substantial risk of recurrence and long-term morbidity. This study examined how adults with diabetes interpreted severe hypoglycemic events and why they declined participation in a community paramedicine program (Diabetes Rescue, Engagement, and Management [Diabetes-REM]) designed to prevent recurrence. RESEARCH DESIGN AND METHODS We conducted semistructured qualitative interviews with adults with type 1 or type 2 diabetes who experienced severe hypoglycemia requiring emergency medical services and declined enrollment in Diabetes-REM. Interviews explored hypoglycemia management experiences and reasons for nonparticipation and were explored using thematic analysis. RESULTS Sixteen adults (44% female; mean age 60 years, range 25–83) participated. Four interrelated themes emerged. First, participants normalized glucose variability as a baseline condition of diabetes and interpreted severe events as situational and correctable when a cause was identifiable, or as inevitable when it was not, rather than as evidence of increased risk. Second, participants relied on prevention systems encompassing habitual routines, caregiver involvement, and glucose-monitoring technologies. Third, severe episodes were frightening and disruptive but typically prompted adjustments to personal management over pursuit of additional clinical support. Finally, reasons for declining Diabetes-REM included time constraints (56%), perceived lack of benefit (25%), and privacy concerns or discomfort with home visits (25%). CONCLUSIONS Among adults who declined a community paramedicine hypoglycemia prevention intervention, severe events were absorbed into existing self-management frameworks rather than viewed as signals of increased risk. Programs targeting hypoglycemia recurrence should account for patients’ risk perceptions and existing management systems, positioning support as complementary rather than corrective.
Single-cell transcriptomic atlas of frontoinsular cortex reveals molecular correlates of selective neuronal vulnerability in FTD
Breevoort, Arnar , Ivanov, Dimitar, Horan-Portelance, Liam , Nana, Alissa , Vatsavayai, Sarat, Miravet, Alex Tudoras, Wallace, Jenelle L., Ding, Jingwen W., Pereira, Felipe L., Fernhoff, Kristen, Gorno-Tempini, Maria Luisa, Spina, Salvatore, Yokoyama, Jennifer S., Rosen, Howard J., Grinberg, Lea T., Jacobs, Frank M. J., Miller, Bruce L., Seeley, William , Pollen, Alex A , Nana, Alissa L , Breevoort, Arnar , Horan-Portelance, Liam , Vatsavayai, Sarat C. , Tudoras, Àlex, Wallace, Jenelle L. , Ding, Jingwen W, Pereira, Felipe L., Fernhoff, Kristen, Gorno‐Tempini, Maria Luisa , Spina, Salvatore , Yokoyama, Jennifer S. , Rosen, Howard J. , Grinberg, Lea T. , Jacobs, Frank M. J. , Seeley, William W.

Mayo Clinic

No container title available | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.13.738307 | PMID 42523377 Get It

Abstract Frontotemporal dementia (FTD) is characterized by selective neuronal vulnerability, yet the features that predispose specific neuron types to degeneration remain unclear. We performed single-nucleus RNA sequencing of frontoinsular cortex, a region affected early in behavioral variant FTD, across individuals with C9orf72 -associated and sporadic FTD-MND spectrum disease. By enriching for large projection neurons, we resolved molecular subtypes of layer 5 extratelencephalic neurons, including von Economo neurons, and identified selective depletion of specific layer 2/3 and layer 5 neuron subtypes, convergent across genotypes. Despite selective neuronal loss, disease-associated transcriptional changes were convergent across excitatory neuron populations, suggesting that they reflect upstream pathophysiology or shared responses to local neurodegeneration. By relating neighborhood-level depletion in disease to gene expression in controls, we found that baseline cellular respiration and ATP synthesis predict neuronal vulnerability in disease. These findings define molecular correlates of selective neuronal vulnerability in FTD and provide a framework linking cell type and state to neurodegeneration.
Bacteriophage Therapy of Mycobacterium abscessus Mastoiditis
Becken, Bradford , Lauer, Michael J , Russell, Daniel A, Garlena, Rebecca A , Cristinziano, Madison, Abad, Lawrence, Dedrick, Rebekah M, Jacobs-Sera, Deborah, Driscoll, Colin, Zwiener, Jennifer, Hatfull, Graham F , Becken, Bradford , Lauer, Michael J , Russell, Daniel A. , Garlena, Rebecca A. , Cristinziano, Madison, Abad, Lawrence , Dedrick, Rebekah M. , Jacobs‐Sera, Deborah , Driscoll, Colin L. W., Zwiener, Jennifer, Hatfull, Graham F.

Mayo Clinic

Clinical Infectious Diseases | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag439 | PMID 42455053 Get It

Abstract We describe a case of a child with macrolide-resistant Mycobacterium abscessus who initially had clinical improvement on a dual β-lactam regimen but continued to have positive cultures. Suitable phages active against the bacterial strain were identified, administered both systemically and directly to the ear, and were associated with microbiological remission.
Evaluating Physician-AI Interaction for Cancer Management: Paving the Path toward Precision Oncology
Hussain, Zubair , Lam, Barbara , Acosta-Perez, Fernando A. , Riaz, Irbaz Bin , Jacobs, Maia , Yee, Andrew J. , Sontag, David , Yee, Andrew J , Riaz, Irbaz B , Jacobs, Maia L. , Sontag, David A.

Mayo Clinic

ACM Transactions on Computing for Healthcare | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1145/3816148 Get It

As machine learning (ML)-based decision support tools proliferate in clinical practice, understanding how clinicians integrate personalized ML predictions alongside randomized controlled trial (RCT) evidence is critical. We designed a web-based clinical decision support system (CDSS) presenting survival and adverse event data from a simulated RCT and ML model across 12 synthetic multiple myeloma scenarios. In a within-subjects study with 32 physicians, we evaluated how clinicians synthesize competing evidence sources to make treatment decisions. When ML and RCT outputs were concordant, physicians reported greater confidence than with RCT data alone. When results were discordant, most physicians shifted toward the ML-supported treatment, often before reviewing any information about model training or validation, suggesting a tendency toward automation bias rather than algorithm avoidance. Despite reporting higher perceived reliability after viewing model quality disclosures, physicians were largely unable to describe the validation procedures they had reviewed. Taken together, these findings reveal that clinicians may over-rely on ML recommendations even when equipped with tools designed to support critical appraisal. We discuss implications for CDSS design, clinician training, and the institutional safeguards needed before ML-based systems are deployed in high-stakes oncology settings.
Early Corticosteroid use and Clinical Outcomes in Patients with Mixed and Cardiogenic Shock
Gastanadui, Maria Gabriela , Murphy, Hannah R. , Shahu, Andi, Safiriyu, Israel , Heck, Cory, Hysolli, Maria, Garimella, Sanjana, Ali, Tariq , Jentzer, Jacob C., Gage, Ann, Katz, Jason N. , Miller, P. Elliott, Jentzer, Jacob C. , Jentzer, Jacob C , Miller, P Elliott , Gastanadui, Maria Gabriela , Safiriyu, Israel , Heck, Cory, Callegari, Santiago , Garimella, Sanjana , Gage, Ann , Jacobs, Mark , Miller, P. Elliott

Mayo Clinic

Journal of Intensive Care Medicine | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261437767 | PMID 42223374 Get It

Background The pathophysiology of CS is complex and is associated with increased inflammation and impaired vascular tone. Corticosteroids are recommended in septic shock and have been proposed as a potential treatment for other types of shock. Objectives We sought to evaluate the clinical outcomes associated with early corticosteroid use in patients with cardiogenic shock (CS). Methods Using a nationally representative database including over 1000 hospitals, we identified adults ≥18 years of age admitted from 2015–2023 with a diagnosis of CS. Patients with adrenal insufficiency, chronic rheumatologic conditions, COVID-19 infection and acute COPD exacerbation were excluded. Using inverse probability treatment weighting (IPTW), we assessed for the association of receiving early corticosteroids (within the first 2 days of admission) versus no early corticosteroids and in-hospital mortality. Results Of the 167,721 identified patients with CS, the mean (SD) age was 65.5 (±15.2) years and 35.0% were women. A total of 13.2% received any corticosteroid within the first 2 days of admission. The most common corticosteroid was hydrocortisone (73.9%). Mortality for those receiving and not receiving early corticosteroids was 48.8% and 29.6% ( p < 0.001), respectively. After IPTW, early corticosteroid use remained associated with a 3.1% (95% confidence interval [CI]: 2.4% to 3.8%, p < 0.001) higher mortality. Among patients with CS and concomitant sepsis, 27.6% received early corticosteroids, which was similarly associated with a higher mortality (weighted mean 5.8% [95% CI: 4.6% to 7.0%, p < 0.001]). Conclusions Approximately 1 in 7 patients with CS received corticosteroids early during their admission, which was associated with higher in-hospital mortality.
Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales
Bhatnagar, Amelia , Harris, Harley , Jacobs, Emily, Bumpus-White, Porscha , Balbuena, Rocío , Stambaugh, Haley, Crayton, Karlos, Haynie, Jennifer, Ilutsik, Justina Quintero, Longo, Cynthia , Singh, Sweety , Murray, Meghan, Sabour, Sarah , Machado, María-José , Simner, Patricia J. , Bhatnagar, Amelia S , Singh, Sweety , Sabour, Sarah , Robinson, Matthew L , Simner, Patricia J , Harris, Harley T. , Jacobs, Emily, Haynie, Jenn , Ilutsik, Justina, Bergman, Yehudit

Mayo Clinic

Journal of Clinical Microbiology | May 22, 2026 | Volume: 64 | Issue: 6 | Pages: No page available

10.1128/jcm.01800-25 | PMID 42171586 Get It

ABSTRACT Metallo-beta-lactamase (MBL)-producing Enterobacterales are a global public health concern. Infections caused by these pathogens are often hard to treat, with few effective agents currently available. While aztreonam-avibactam only recently gained U.S. and European regulatory approval, laboratories have implemented laboratory-developed tests (LDTs) using existing aztreonam and ceftazidime-avibactam reagents. We sought to compare the performance of four phenotypic methods, up to three reagent manufacturers, and two media manufacturers. One hundred two MBL-producing Enterobacterales isolates were evaluated at two sites (Centers for Disease Control and Prevention [CDC] and Johns Hopkins University [JHU] School of Medicine). The performance of four methods was evaluated: broth disk elution (BDE), disk stacking (DS), gradient diffusion strip stacking (SS), and a strip-to-disk proximity (strip-disk) method, which were compared to reference broth microdilution (rBMD) tested in parallel. Respective category agreement for CDC and JHU was 92.2% and 96.1% for BDE, 51%–76.5% and 31%–49% for DS, 71.6%–86.3% and 83.3%–86.3% for SS, and 82.4%–87.3% and 80%–89.2% for the strip-disk method. The SS essential agreement ranged from 46.1% to 62.7% for JHU and 54.9% to 92.2% for CDC. Interlaboratory reproducibility was 93.1% for rBMD, 92.2% for BDE, 47.1%–53.1% for DS, 76.5%–80% for SS, and 87.3%–88.9% for strip-disk. BDE was the only method that exceeded acceptable performance of >90% accuracy and reproducibility. DS had the lowest and most variable performance between sites and among the different disk manufacturers used. LDTs for combination testing can be highly variable, and further work is needed to improve standardization and harmonization to achieve accurate and reliable results for clinical purposes. IMPORTANCE Carbapenem-resistant Enterobacterales are classified as an urgent public health threat in the Centers for Disease Control and Prevention’s 2019 Antibiotic Resistance Threats Report. Among the most concerning resistance mechanisms are carbapenemase enzymes encoded on mobile genetic elements, which can spread rapidly between bacteria. Of the various carbapenemases, metallo-beta-lactamases are particularly challenging, as they confer resistance to nearly all beta-lactams, and current treatment options remain limited. While aztreonam-avibactam has been U.S. Food and Drug Administration (FDA)-approved for treating certain infections with limited or no alternative treatment options, no FDA-cleared susceptibility test is yet available. In this context, laboratory-developed methods, such as combination testing of aztreonam and ceftazidime-avibactam, play a critical role in guiding therapy. Our study evaluates several of the more common laboratory-developed tests compared to reference broth microdilution and found that broth disk elution was the most accurate; in contrast, other methods had variable performance, some demonstrating limited reliability and being prone to overcalling resistance.